Karyopharm Therapeutics Inc (KPTI):企業の財務・戦略的SWOT分析

◆英語タイトル:Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1646
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Karyopharm Therapeutics Inc (KPTI) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Karyopharm Therapeutics Inc (Karyopharm Therapeutic) discovers and develops novel drugs for the treatment of various cancer types. The company develops small molecule selective inhibitors of nuclear export compounds that combat the nuclear export of XPO1 protein. Its pipeline drug candidates include selinexor, verdinexor, eltanexor, and oral KPT-9274. Karyopharm drug candidates are indicated for the treatment of various hematological and solid tumor malignancies including multiple myeloma, acute myeloid leukemia, diffuse large B-cell lymphoma, liposarcoma, glioblastoma and gynecological malignancies. The company has operations in the US, Israel and Germany. Karyopharm is headquartered in Newton, Massachusetts, the US.

Karyopharm Therapeutics Inc Key Recent Developments

Mar 12,2020 Karyopharm expands executive leadership team with the appointment of John Demaree as Chief Commercial Officer
Feb 13,2020 Karyopharm reports fourth quarter and full year 2019 financial results and highlights recent company progress
Nov 04,2019 Karyopharm reports third quarter 2019 financial results and highlights recent company progress
May 09,2019 Karyopharm reports first quarter 2019 financial results and highlights recent company progress

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Karyopharm Therapeutics Inc – Key Facts
Karyopharm Therapeutics Inc – Key Employees
Karyopharm Therapeutics Inc – Key Employee Biographies
Karyopharm Therapeutics Inc – Major Products and Services
Karyopharm Therapeutics Inc – History
Karyopharm Therapeutics Inc – Company Statement
Karyopharm Therapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Karyopharm Therapeutics Inc – Business Description
R&D Overview
Karyopharm Therapeutics Inc – Corporate Strategy
Karyopharm Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Karyopharm Therapeutics Inc – Strengths
Karyopharm Therapeutics Inc – Weaknesses
Karyopharm Therapeutics Inc – Opportunities
Karyopharm Therapeutics Inc – Threats
Karyopharm Therapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Karyopharm Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 12, 2020: Karyopharm expands executive leadership team with the appointment of John Demaree as Chief Commercial Officer
Feb 13, 2020: Karyopharm reports fourth quarter and full year 2019 financial results and highlights recent company progress
Nov 04, 2019: Karyopharm reports third quarter 2019 financial results and highlights recent company progress
May 09, 2019: Karyopharm reports first quarter 2019 financial results and highlights recent company progress
Mar 01, 2019: Karyopharm reports fourth quarter and full year 2018 financial results and provides corporate update
Feb 25, 2019: Karyopharm strengthens management team with appointment of Michael P. Mason as chief financial officer
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Karyopharm Therapeutics Inc, Key Facts
Karyopharm Therapeutics Inc, Key Employees
Karyopharm Therapeutics Inc, Key Employee Biographies
Karyopharm Therapeutics Inc, Major Products and Services
Karyopharm Therapeutics Inc, History
Karyopharm Therapeutics Inc, Subsidiaries
Karyopharm Therapeutics Inc, Key Competitors
Karyopharm Therapeutics Inc, Ratios based on current share price
Karyopharm Therapeutics Inc, Annual Ratios
Karyopharm Therapeutics Inc, Annual Ratios (Cont...1)
Karyopharm Therapeutics Inc, Interim Ratios
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Karyopharm Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Karyopharm Therapeutics Inc, Performance Chart (2015 - 2019)
Karyopharm Therapeutics Inc, Ratio Charts
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Karyopharm Therapeutics Inc (KPTI):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Medshape Inc-医療機器分野:企業M&A・提携分析
    Summary Medshape Inc (MedShape), formerly MedShape Solutions Inc is a medical device company that develops and manufactures orthopedic devices for the orthopedic healthcare markets. The company’s products include dynanail ankle arthrodesis nail, eclipse soft tissue anchor, exoshape teno soft tissue …
  • Fluidigm Corp (FLDM):企業の財務・戦略的SWOT分析
    Summary Fluidigm Corp (Fluidigm), formerly Mycometrix Corp, develops, manufactures, and markets life science analytical and preparatory systems for mass cytometry, high-throughput genomics, and single-cell genomics markets. The company offers analytical systems and instruments, preparatory instrumen …
  • Depomed, Inc.:企業の戦略・SWOT・財務情報
    Depomed, Inc. - Strategy, SWOT and Corporate Finance Report Summary Depomed, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Ferrovial SA (FER):企業の財務・戦略的SWOT分析
    Ferrovial SA (FER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Roquette Freres SA:企業の戦略的SWOT分析
    Roquette Freres SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Voith Hydro Holding GmbH & Co KG:企業の戦略的SWOT分析
    Voith Hydro Holding GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Abbott Diabetes Care Inc-医療機器分野:企業M&A・提携分析
    Summary Abbott Diabetes Care Inc (ADC), formerly TheraSense Inc, a subsidiary of Abbott Laboratories, is a medical device company that discovers, develops, manufactures, and markets pharmaceuticals and medical products for personal use and hospital use. The company’s products include glucose monitor …
  • Trinidad Drilling Ltd (TDG):企業の財務・戦略的SWOT分析
    Summary Trinidad Drilling Ltd (Trinidad Drilling) is an oil and gas company that offers drilling services. The company’s services include land and barge drilling, coring and presetting, well servicing, rig design and management, rig fleet management, and technical support services. Its in-house manu …
  • TUI AG (TUI1):企業の財務・戦略的SWOT分析
    TUI AG (TUI1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • AB Sciex LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary AB Sciex LLC (Sciex), a subsidiary of Danaher Corp, is a provider of life science analytical technologies. The company provides mass spectrometry solutions combined with capillary electrophoresis and liquid chromatography. Its product portfolio includes liquid chromatography-mass spectromete …
  • McGill University:製薬・医療:M&Aディール及び事業提携情報
    Summary McGill University (McGill) is a medical-doctoral university. The institute offers undergraduate, graduate, post-graduate courses besides research programs. It provides academic courses across various disciplines including agricultural and environmental sciences, arts, dentistry, education, e …
  • Cryostar SAS:企業の戦略的SWOT分析
    Cryostar SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Trustpower Limited:企業の戦略的SWOT分析
    Trustpower Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Valneva SE (VLA):製薬・医療:M&Aディール及び事業提携情報
    Summary Valneva SE (Valneva) is a biotech company that develops lifesaving vaccines. The company’s products include IXIARO, a vaccine indicated for the prevention of Japanese encephalitis; and Dukoral, a vaccine indicated for the prevention of cholera and diarrhea; clostridium difficile, lyme, chiku …
  • University of Maryland Medical Center Corp:企業の戦略的SWOT分析
    University of Maryland Medical Center Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • Tecpetrol SA:企業の戦略的SWOT分析
    Tecpetrol SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • African Development Bank Group:企業の戦略的SWOT分析
    African Development Bank Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Systex Corp (6214):企業の財務・戦略的SWOT分析
    Systex Corp (6214) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Merz Pharma GmbH & Co. KGaA:企業のM&A・事業提携・投資動向
    Merz Pharma GmbH & Co. KGaA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Merz Pharma GmbH & Co. KGaA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Lam Research Corporation (LRCX):企業の財務・戦略的SWOT分析
    Lam Research Corporation (LRCX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆